GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (“NK” ...
Cash position of €7.5 million as of December 31, 2024 BioChaperone Lispro final dosing of Phase 3 triggered a $10 million revenue recognition, and top-line data are expected in mid-2025 ...
Public bitcoin miners are rushing to build AI business lines, but there’s still room for their original mandate, says this ...
TipRanks on MSN15h
Bausch + Lomb price target lowered to $18 from $19 at Morgan StanleyMorgan Stanley analyst Patrick Wood lowered the firm’s price target on Bausch + Lomb (BLCO) to $18 from $19 and keeps an Equal Weight rating on ...
"In Q4, we delivered strong marketplace revenue growth, operating leverage and positive Adjusted EBITDA,” said James Miln, Xometry's CFO. "Our record marketplace gross margin of 34.5% and operating ...
In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Invivyd (IVVD – Research Report), with a price ...
H.C. Wainwright analyst Edward White maintained a Hold rating on 60 Degrees Pharmaceuticals, Inc. (SXTP – Research Report) today. The company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback